APA (7th ed.) Citation

RA, F., M, F., P, K., M, B., D, G., CL, B., . . . R, P. (2023). Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. Frontiers in endocrinology, 14, 1165681. https://doi.org/10.3389/fendo.2023.1165681

Chicago Style (17th ed.) Citation

RA, Feelders, et al. "Long-term Efficacy and Safety of Subcutaneous Pasireotide Alone or in Combination with Cabergoline in Cushing's Disease." Frontiers in Endocrinology 14 (2023): 1165681. https://doi.org/10.3389/fendo.2023.1165681.

MLA (9th ed.) Citation

RA, Feelders, et al. "Long-term Efficacy and Safety of Subcutaneous Pasireotide Alone or in Combination with Cabergoline in Cushing's Disease." Frontiers in Endocrinology, vol. 14, 2023, p. 1165681, https://doi.org/10.3389/fendo.2023.1165681.